Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Caffeine levels may help in diagnosing Parkinson’s disease

Staff Writer
Staff Writer 5 years ago
Updated 2019/06/28 at 7:42 PM
Share
SHARE

Researchers have uncovered a new biomarker that may help in the diagnosis of Parkinson’s disease: caffeine.
According to a study, published in the journal Neurology, examining the level of caffeine in the blood could help detect the neurodegenerative disease early.

“Previous studies have shown a link between caffeine and a lower risk of developing Parkinson’s disease, but we haven’t known much about how caffeine metabolizes within the people with the disease,” said Shinji Saiki, MD, the study’s author.

The study began by analyzing 108 participants with a history of Parkinson’s disease, along with another 31 participants, of which did not have the disease. All participants were studied for an estimated six years.

Researchers initiated tests to measure caffeine in the blood, in addition to 11 byproducts that contribute to the metabolism of caffeine. During the study, both groups of participants consumed the same amount of caffeine — two cups of coffee each day.


The findings reveal that participants with Parkinson’s disease had significantly lower traces of caffeine in the blood.
The average caffeine level found was 79 picomoles per 10 microliters for participants without the disease. Meanwhile, the caffeine level for the group with Parkinson’s was 24 picomoles per 10 microliters.

“The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis,” according to the results.

“Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies,” the study concluded.

You Might Also Like

New study explores test that can detect Alzheimer’s years before diagnosis

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

New research finds Alzheimer’s risk factors affect males and females very differently

Study establishes critical role in regulating excessive folding of gyri in brain

TAGGED: biomarkers, caffeine, diagnosis, parkinson's disease
Staff Writer January 13, 2018
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Perfectionism is on the rise among young millennials
Next Article Anxiety may be an early indicator of Alzheimer’s disease

Recommended

Clinical

New study explores test that can detect Alzheimer’s years before diagnosis

1 Min Read
Clinical

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

1 Min Read
Clinical

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

1 Min Read
Clinical

New research finds Alzheimer’s risk factors affect males and females very differently

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?